Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target central nervous system rare disease and diabetic complications in the United States.

Its lead product candidate is AT-007 that has completed phase III for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG.

The company also develops AT-001 that is in phase III clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy.

Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.